|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Towards 6G wireless communication networks:vision,enabling technologies,and new paradigm shifts显示文摘The fifth generation(5G)wireless communication networks are being deployed worldwide from 2020 and more capabilities are in the process of being standardized,such as mass connectivity,ultra-reliability,and guaranteed low latency.However,5G will not meet all requirements of the future in 2030 and beyond,and sixth generation(6G)wireless communication networks are expected to provide global coverage,enhanced spectral/energy/cost efficiency,better intelligence level and security,etc.To meet these requirements,6G networks will rely on new enabling technologies,i.e.,air interface and transmission technologies and novel network architecture,such as waveform design,multiple access,channel coding schemes,multi-antenna technologies,network slicing,cell-free architecture,and cloud/fog/edge computing.Our vision on 6G is that it will have four new paradigm shifts.First,to satisfy the requirement of global coverage,6G will not be limited to terrestrial communication networks,which will need to be complemented with non-terrestrial networks such as satellite and unmanned aerial vehicle(UAV)communication networks,thus achieving a space-airground-sea integrated communication network.Second,all spectra will be fully explored to further increase data rates and connection density,including the sub-6GHz,millimeter wave(mmWave),terahertz(THz),and optical frequency bands.Third,facing the big datasets generated by the use of extremely heterogeneous networks,diverse communication scenarios,large numbers of antennas,wide bandwidths,and new service requirements,6G networks will enable a new range of smart applications with the aid of artificial intelligence(AI)and big data technologies.Fourth,network security will have to be strengthened when developing 6G networks.This article provides a comprehensive survey of recent advances and future trends in these four aspects.Clearly,6G with additional technical requirements beyond those of 5G will enable faster and further communications to the extent that the boundary between physical and cyber worlds disappears. | Xiaohu YOU Cheng-Xiang WANG Jie HUANG Xiqi GAO Zaichen ZHANG Mao WANG Yongming HUANG Chuan ZHANG Yanxiang JIANG Jiaheng WANG Min ZHU Bin SHENG Dongming WANG Zhiwen PAN Pengcheng ZHU Yang YANG Zening LIU Ping ZHANG Xiaofeng TAO Shaoqian LI Zhi CHEN Xinying MA Chih-Lin I Shuangfeng HAN Ke LI Chengkang PAN Zhimin ZHENG Lajos HANZO Xuemin(Sherman)SHEN Yingjie Jay GUO Zhiguo DING Harald HAAS Wen TONG Peiying ZHU Ganghua YANG Jun WANG Erik GLARSSON Hien Quoc NGO Wei HONG Haiming WANG Debin HOU Jixin CHEN Zhe CHEN Zhangcheng HAO Geoffrey Ye LI Rahim TAFAZOLLI Yue GAO HVincent POOR Gerhard P.FETTWEIS Ying-Chang LIANG | 2021 | Science China(Information Sciences)2021，64，1： | 122 |
| 2 | Stereotactic body radiation therapy for non-small cell lung cancer:A review显示文摘Stereotactic body radiation therapy(SBRT) is the treatment of choice for medically inoperable patients with early stage non-small cell lung cancer(NSCLC). A literature search primarily based on PubMed electronic databases was completed in July 2018. Inclusion and exclusion criteria were determined prior to the search, and only prospective clinical trials were included. Nineteen trials from 2005 to 2018 met the inclusion criteria, reporting the outcomes of 1434 patients with central and peripheral early stage NSCLC. Patient eligibility,prescription dose and delivery, and follow up duration varied widely. Threeyears overall survival ranged from 43% to 95% with loco-regional control of up to 98% at 3 years. Up to 33% of patients failed distantly after SBRT at 3 years. SBRT was generally well tolerated with 10%-30% grade 3-4 toxicities and a few treatment-related deaths. No differences in outcomes were observed between conventionally fractionated radiation therapy and SBRT, central and peripheral lung tumors, or inoperable and operable patients. SBRT remains a reasonable treatment option for medically inoperable and select operable patients with early stage NSCLC. SBRT has shown excellent local and regional control with toxicity rates equivalent to surgery. Decreasing fractionation schedules have been consistently shown to be both safe and effective. Distant failure is common, and chemotherapy may be considered for select patients. However, the survival benefit of additional interventions, such as chemotherapy, for early stage NSCLC treated with SBRT remains unclear. | Kavitha M Prezzano Sung Jun Ma Gregory M Hermann Charlotte I Rivers Jorge A Gomez-Suescun Anurag K Singh | 2019 | World Journal of Clinical Oncology2019，10，1： | 10 |
| 3 | Mutation of kri1l causes definitive hematopoiesis failure via PERK-dependent excessive autophagy induction显示文摘 | Xiao-E Jia Ke Ma Tao Xu Lei Gao Shuang Wu Cong Fu Wenjuan Zhang Zhizhang Wang Kaiyu Liu Mei Dong Changbin Jing Chunguang Ren Zhiwei Dong Yi Chen Yi Jin Qiuhua Huang Xing Chang Min Deng Li Li Lingfei Luo Jun Zhu Yongjun Dang Hung-Chun Chang Leonard I Zon Yi Zhou Saijuan Chen Weijun Pan | 2015 | Cell Research2015，25，8： | 8 |
| 4 | Long-term outcomes of interventions for radiation-induced xerostomia:A review显示文摘Xerostomia, or dry mouth, is a significant problem affecting quality of life in patients treated with radiation therapy for head and neck cancer. Strategies for reduction of xerostomia burden vary widely, with options including: sialagogue medications, saliva substitutes, acupuncture, vitamins, hyperbaric oxygen,submandibular gland transfer, and acupuncture or associated treatments. In this review, we sought to evaluate long-term outcomes of patients treated with various interventions for radiation-induced xerostomia. A literature search was performed using the terms 'xerostomia' and 'radiation' or 'radiotherapy'; all prospective clinical trials were evaluated, and only studies that reported 1 year follow up were included. The search results yielded 2193 studies, 1977 of which were in English. Of those, 304 were clinical trials or clinical studies. After abstract review, 23 trials were included in the review evaluating the following treatment modalities: pilocarpine(three); cevimeline(one); amifostine(eleven);submandibular gland transfer(five); acupuncture like transcutaneous electrical nerve stimulation(ALTENS)(one); hyperbaric oxygen(one); and acupuncture(one). Pilocarpine, cevimeline, and amifostine have been shown in some studies to improve xerostomia outcomes, at the cost of toxicity. ALTENS has similar efficacy with fewer side effects. Submandibular gland transfer is effective but requires an elective surgery, and thus may not always be appropriate or practical.The use of intensity-modulated radiation therapy, in addition to dose deescalation in select patients, may result in fewer patients with late xerostomia,reducing the need for additional interventions. | Sung Jun Ma Charlotte I Rivers Lucas M Serra Anurag K Singh | 2019 | World Journal of Clinical Oncology2019，10，1： | 4 |
| 5 | STELLADELIN D,A NEW CYCLIC UNDECAPEPTIDE FROM STELLARIA DELAVAYI显示文摘STELLADELIND,ANEWCYCLICUNDECAPEPTIDEFROMSTELLARIADELAVAYI￥YuRuiZHAO;JunZHOU;XianKaiWANG;XiaoLinHUANG;HouMingWU;ChangXiangCHEN... | Yu Rui ZHAO Jun ZHOU Xian Kai WANG Xiao Lin HUANG Hou Ming WU Chang Xiang CHENG (Depepartment of Medicinal Chemistry of Natural Products,School ofPharmacy, West China University of Medical Sciences,Chengdu, 610041)(Laboratory of Phytochemistry,Kunming I | 1996 | Chinese Chemical Letters1996，7，3： | 4 |
| 6 | A NEW CYCLOPEPTIDE FROM ARENARIA JUNCEA显示文摘A NEW CYCLOPEPTIDE FROM ARENARIA JUNCEAANEWCYCLOPEPTIDEFROMARENARIAJUNCEAYuRuiZHAO;JunZHOU;XianKaiWANG;XiaoLinHUANG;HouMingWU... | Yu Rui ZHAO Jun ZHOU Xian Kai WANG Xiao Lin HUANG Hou Ming WU Tong Fang ZHAO(Department of Medicinal Chemistry of Natural Products, School of Pharmacy, West China University of Medical Sciences. Chengdu, 610041)(Laboratory of Phytochemistry, Kunming I | 1994 | Chinese Chemical Letters1994，5，9： | 2 |
| 7 | Use of ADME studies to confirm the safety of ε-polylvsine as a preservative in food 显示文摘 | Jun H Takafumi I Shin-ichi N | 2003 | Regulatory Toxicology and Pharmacology2003，37，： | 1 |
| 8 | A model for predicting the heat flow into the workpiece in dry drilling显示文摘 | BONE M JUN N I | 2002 | Journal of Manufacturing Science and Engineering2002，124，4： | 1 |
| 9 | Use of ADME studies to confirm the safety of ε-polylysine as a preservative in food显示文摘 | Takafumi I Shin-ichi N | 2003 | Regulatory Toxicology and Pharmacology2003，37，： | 1 |
| 10 | 查看详情显示文摘 | Kim S D Baek S C Lee Y J Jun K W Kim M J Yoo I S | | 0，，： | 1 |
| 11 | Defect structure induced by iron injection in WC-Co显示文摘 | BAIK S I CHOI E G JUN J H ICIM Y W | 2008 | Scripta Materialia2008，58，： | 1 |
| 12 | Comparison of lasing performance of Tm,Ho:YLF laser by use of single and double cavities显示文摘 | JUN I HAYATO N HIROSHI H | 2000 | Appl Opt2000，39，15： | 1 |
| 13 | Carbon isotopic analysis of atmospheric methane in urban and suburban areas:fossil and non-fossil methane from local sources显示文摘 | Jun M Koichiro N Takao I | 1998 | Atmospheric Environment1998，32，： | 1 |
| 14 | Removal of humic acids by flotation 显示文摘 | Zouboulis Anastasios I Jun Wu | 2003 | Colloids and Surfaces A:Physicochemlcal and Engineering Aspects2003，231，13： | 1 |
| 15 | Endoscopic thyroidec tomy by the breast approach: a single institution's 9 years experience显示文摘 | Akira S Jun N Kenichiro I | 2008 | World J Surg2008，32，3： | 1 |
| 16 | Physical activity and body mass index and their associations with the development of type 2 diabetes in korean men显示文摘 | Lee DC Park I Jun TW | 2012 | Am J Epidemiol2012，176，1： | 1 |
| 17 | Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative,open trial显示文摘BACKGROUND Few studies have compared the efficacy and safety profile of a tailored eradication(TR)strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy(EBQT)for first-line eradication of Helicobacter pylori(H.pylori)in Korean patients.AIM To compare the efficacy and safety of a TR strategy and those of EBQT regimen as first-line eradication therapy for H.pylori.METHODS This is an open-label,comparative study in which we prospectively enrolled patients over 18 years of age with H.pylori infection and retrospectively reviewed their data.H.pylori-positive patients diagnosed by rapid urease test,Giemsa staining,or dual priming oligonucleotide polymerase chain reaction(DPO-PCR)were enrolled from May 2016 to September 2018 at Gil Medical Center.Patients with H.pylori infection received either a TR regimen or the EBQT regimen.In the tailored therapy group that underwent DPO-PCR testing,patients with A2142G and/or A2143G point mutations were treated with a bismuth-containing quadruple regimen.The eradication rate,patient-reported side effect rate,and H.pylori eradication success rate were evaluated and compared between the groups.RESULTS A total of 150 patients were assigned to the TR(n=50)or EBQT group(n=100).The first-line eradication rate of H.pylori did not differ between the groups(96.0%vs 95.7%,P=0.9).The rate of eradication-related side effects for TR was 12.0%,which differed significantly from that of EBQT(43.0%)for first-line treatment(P<0.001).CONCLUSION DPO-PCR-based TR for H.pylori eradication may be equally efficacious,with less treatment-related complications,compared to EBQT in Korea,where clarithromycin resistance is high. | Youn I Choi Jun Won Chung Dong Kyun Park Kyoung Oh Kim Kwang An Kwon Yoon Jae Kim Ja Young Seo | 2019 | World Journal of Gastroenterology2019，25，46： | 1 |
| 18 | Polycrystalline thin film transistors fabricated by FALC (field aided lateral crystallization) technique显示文摘 | SONG K S LEE J B JUN S I | 2003 | J Mater Sci Lett2003，18，15： | 1 |
| 19 | Bifurcations of traveling wave solution in generalized Pochhammer-Chree equation显示文摘 | L I J I B I N ZHANG L I JUN | 2002 | Chaos Soitons and Fractals2002，14，： | 1 |
| 20 | Effect of heat and moisture exchanger(HME)positioning on inspiratory gas humidification显示文摘 | Daisuke I Jun O Masaj N | 2006 | BMC Pulm Med2006，6，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员